Articles Vol. 66 No. 2 04/03/2025

18. PAZOPANIB FOR METASTATIC RENAL CELL CARCINOMA: A CASE REPORT

Le Vinh Giang1,2, Bui Hong Ngoc1,2, Nguyen Thi Huong Giang1,2
1 Hanoi Medical University
2 Trường Đại học Y Hà Nội
Corresponding author: giangvinhle@hmu.edu.vn
DOI: 10.52163/yhc.v66i2.2097
13 Views
13 Downloads
Keywords
Metastatic RCC pazopanib effectiveness PFS side effects
Abstract

Summary: Kidney cancer is a less common type of cancer and has a better prognosis than many other types of cancer. Kidney cancer has many different types of histopathology but renal cell carcinoma (RCC) accounts for 90% of kidney cancer cases. Pazopanib has been approved for the first-line treatment of metastatic renal cell carcinoma.

Objectives: describe the initial clinical and imaging responses, follow-up the progression-free survival (PFS) and common side effects of pazopanib.

Methods: report a case of metastatic RCC treated in the first line with pazopanib.

Results: the patient got a partial response after 6 months of pazopanib treatment, and stable disease after 29 months of the treatment. Side effects when taking the drug include fatigue, hypertension, and diarrhea. Side effects were controlled without having to adjust the pazopanib dose.

Conclusion: pazopanib is a targeted drug with high effectiveness, long disease-free survival, and safety in first-line treatment of patients with metastatic RCC.

References
[1]
. Moch, H., et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 2016, 70-93. Google Scholar
[2]
. Motzer RJ, Bander NH, Nanus DM (1996) Renal cell carcinoma Engl J Med 335: 865 - 875. Google Scholar
[3]
. HurwitzH, Dowlati A, Savage S et al: Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with soild tumors. JClin Oncol, 2005, 23-195. Google Scholar
[4]
. Bộ Y tế. Thông tư số 26/2019/TT-BYT Quy định về danh mục thuốc hiếm, 2019. Google Scholar
[5]
. Stroobants S, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer, 2003. Google Scholar
[6]
. Sternberg CN, Davis ID. Mardiak J, Szcylik C, Lee Wagstaff J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: result of randomized phasIII trial. J Clin Oncol, 2010, 28: 1061- 1068. Google Scholar
[7]
. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J et al. Pazopanib versus sunitinb in metastatic renal cell carcinoma. Nengl J Med, 2013, 369: 722 - 731. Google Scholar
[8]
. Delea TE, Amdahl J,Diaz J, et al. Cost-Effectiveness of pazopanib versus sunitinib for renal cancer in United States, J Manag care spec pharm. 2015, 1: 46 - 54. Google Scholar